Attached files
file | filename |
---|---|
8-K - FORM 8-K - ImmunoCellular Therapeutics, Ltd. | rrd387554.htm |
EX-99 - PRESS RELEASE DATED AUGUST 7, 2013 - ImmunoCellular Therapeutics, Ltd. | rrd387554_39820.htm |
Condensed Balance Sheets | ||||||||||||||||
6/30/2013 | 12/31/2012 | |||||||||||||||
(Unaudited) | ||||||||||||||||
|
|
|
|
|||||||||||||
Cash | $ | 25,452,382 | $ 26,216,668 | |||||||||||||
Other current assets | 402,075 | 714,508 | ||||||||||||||
Non current assets | 326,804 | 88,025 | ||||||||||||||
|
|
|
|
|||||||||||||
Total assets | $ | 26,181,261 | $ 27,019,201 | |||||||||||||
|
|
|
||||||||||||||
Current liabilities | $ | 823,266 | $ 1,098,307 | |||||||||||||
Warrant liability | 2,311,391 | 2,852,880 | ||||||||||||||
Shareholders' equity | 23,046,604 | 23,068,014 | ||||||||||||||
|
|
|
||||||||||||||
$ | 26,181,261 | $ 27,019,201 | ||||||||||||||
|
|
|
||||||||||||||
Condensed Statement of Operations (Unaudited) | ||||||||||||||||
3 months | 3 months | 6 months | 6 months | |||||||||||||
ended | ended | ended | ended | |||||||||||||
6/30/2013 | 6/30/2012 | 6/30/2013 | 6/30/2012 | |||||||||||||
|
|
|
|
|
|
|
||||||||||
Revenue | $0 | $0 | $0 | $0 | ||||||||||||
Research and development | 1,213,570 | 2,189,633 | 2,628,831 | 4,188,169 | ||||||||||||
Stock based compensation | 179,946 | 103,617 | 344,074 | 348,724 | ||||||||||||
General and administrative | 788,420 | 837,322 | 1,557,687 | 1,643,120 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Loss before other expenses | (2,181,936) | (3,130,572) | (4,530,592) | (6,180,013) | ||||||||||||
Interest income | 4,095 | 1,975 | 10,643 | 3,009 | ||||||||||||
Financing expense | 0 | 0 | 0 | (368,524) | ||||||||||||
Change in fair value of warrant liabilty | 2,027,512 | (3,323,220) | (604,171) | (7,795,724) | ||||||||||||
|
|
|
|
|
|
|
||||||||||
Net loss | ($150,329) | ($6,451,817) | ($5,124,120) | ($14,341,252) | ||||||||||||
|
|
|
|
|
|
|||||||||||
Net loss per share, basic and diluted: | $ | (0.00) | $ | (0.16) | $ | (0.10) | $ | (0.37) | ||||||||
|
|
|
|
|
|
|
|